October 26, 2015

Novocure Reports Third Quarter 2015 Operating and Financial Results

FDA approved Optune™ in combination with temozolomide for the treatment of newly diagnosed glioblastoma on October 5, 2015 CE Mark was placed on the second generation Optune system. First patients treated in Europe with the newly designed, smaller, lighter system 468 active patients at quarter… Read More
learn more
October 26, 2015

Novocure Reports Third Quarter 2015 Operating and Financial Results

FDA approved Optune™ in combination with temozolomide for the treatment of newly diagnosed glioblastoma on October 5, 2015 CE Mark was placed on the second generation Optune system. First patients treated in Europe with the newly designed, smaller, lighter system 468 active patients at quarter… Read More
learn more
October 26, 2015

Novocure Reports Third Quarter 2015 Operating and Financial Results

FDA approved Optune™ in combination with temozolomide for the treatment of newly diagnosed glioblastoma on October 5, 2015 CE Mark was placed on the second generation Optune system. First patients treated in Europe with the newly designed, smaller, lighter system 468 active patients at quarter… Read More
learn more
October 19, 2015

NovoCure Limited Announces Closing of Partial Exercise of IPO Over-Allotment Option

October 19, 2015 04:05 PM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–NovoCure Limited (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced the closing today of a partial exercise of the over-allotment option by… Read More
learn more
October 19, 2015

NovoCure Limited Announces Closing of Partial Exercise of IPO Over-Allotment Option

October 19, 2015 04:05 PM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–NovoCure Limited (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced the closing today of a partial exercise of the over-allotment option by… Read More
learn more
October 19, 2015

NovoCure Limited Announces Closing of Partial Exercise of IPO Over-Allotment Option

October 19, 2015 04:05 PM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–NovoCure Limited (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced the closing today of a partial exercise of the over-allotment option by… Read More
learn more
October 16, 2015

Novocure to Offer On Demand Optune Certification Training for the Radiation Oncology Community at ASTRO 2015

Optune is the first FDA-approved therapy in more than a decade to demonstrate statistically significant extension of survival in newly diagnosed glioblastoma patients Optune is the first FDA-approved therapy in more than a decade to demonstrate statistically significant extension of survival in newly diagnosed glioblastoma patients… Read More
learn more
October 16, 2015

Novocure to Offer On Demand Optune Certification Training for the Radiation Oncology Community at ASTRO 2015

Optune is the first FDA-approved therapy in more than a decade to demonstrate statistically significant extension of survival in newly diagnosed glioblastoma patients Optune is the first FDA-approved therapy in more than a decade to demonstrate statistically significant extension of survival in newly diagnosed glioblastoma patients… Read More
learn more
October 16, 2015

Novocure to Offer On Demand Optune Certification Training for the Radiation Oncology Community at ASTRO 2015

Optune is the first FDA-approved therapy in more than a decade to demonstrate statistically significant extension of survival in newly diagnosed glioblastoma patients Optune is the first FDA-approved therapy in more than a decade to demonstrate statistically significant extension of survival in newly diagnosed glioblastoma patients… Read More
learn more
October 16, 2015

Novocure to Report Third Quarter 2015 Financial Results on Monday, October 26

October 16, 2015 11:54 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today that it will report financial results for the third quarter of 2015… Read More
learn more